GSK-3 inhibition induced anti-survival effects in pancreatic cancer cells, associated with downregulation of NF-κB activity and reduced expression of anti-apoptotic target genes such as XIAP, BcL-XL, and cyclin D1 [14]. This evidence concerns the gene XIAP and pancreatic neoplasm.